NZ721217A - Biaryl inhibitors of bruton’s tyrosine kinase - Google Patents
Biaryl inhibitors of bruton’s tyrosine kinaseInfo
- Publication number
- NZ721217A NZ721217A NZ721217A NZ72121714A NZ721217A NZ 721217 A NZ721217 A NZ 721217A NZ 721217 A NZ721217 A NZ 721217A NZ 72121714 A NZ72121714 A NZ 72121714A NZ 721217 A NZ721217 A NZ 721217A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bruton
- tyrosine kinase
- inhibitors
- biaryl
- biaryl inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914886P | 2013-12-11 | 2013-12-11 | |
| PCT/US2014/069853 WO2015089337A1 (en) | 2013-12-11 | 2014-12-11 | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ721217A true NZ721217A (en) | 2021-12-24 |
Family
ID=52302344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ721217A NZ721217A (en) | 2013-12-11 | 2014-12-11 | Biaryl inhibitors of bruton’s tyrosine kinase |
Country Status (32)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029046A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| PT3080103T (pt) | 2013-12-11 | 2018-07-23 | Sunesis Pharmaceuticals Inc | Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia |
| JP2018521029A (ja) * | 2015-06-10 | 2018-08-02 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ブルトン型チロシンキナーゼのビアリール阻害剤のアジピン酸塩形態及び組成物 |
| MA42510A (fr) | 2015-06-10 | 2018-06-06 | Biogen Ma Inc | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton |
| US10821104B2 (en) * | 2015-12-07 | 2020-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Five-membered heterocyclic amides WNT pathway inhibitor |
| JO3793B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN109477073B (zh) * | 2016-03-31 | 2024-04-12 | 来恩生物医药私人有限公司 | 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞 |
| US10710993B2 (en) | 2016-06-27 | 2020-07-14 | Hangzhou REX Pharmaceutical Co., LTD. | Benzofuran pyrazole amine kinase inhibitor |
| WO2018017153A1 (en) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate forms and compositions of bruton's tyrosine kinase inhibitors |
| US10954216B2 (en) | 2016-12-27 | 2021-03-23 | Riken | BMP-signal-inhibiting compound |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
| EP3737677B1 (en) | 2018-01-10 | 2021-11-03 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
| CA3252332A1 (en) | 2018-01-19 | 2025-06-04 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| US20190330226A1 (en) * | 2018-04-26 | 2019-10-31 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| TW202016097A (zh) | 2018-05-14 | 2020-05-01 | 美商百健Ｍａ公司 | 布魯頓氏酪胺酸激酶之抑制劑 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| WO2020005888A1 (en) | 2018-06-26 | 2020-01-02 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| MA53914A (fr) * | 2018-10-15 | 2021-08-25 | Biogen Ma Inc | Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton |
| WO2020118683A1 (en) * | 2018-12-14 | 2020-06-18 | Lynk Pharmaceuticals Co. Ltd. | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| JP7747523B2 (ja) * | 2019-05-15 | 2025-10-01 | バイオジェン・エムエイ・インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| WO2021133894A1 (en) * | 2019-12-23 | 2021-07-01 | Biogen Ma Inc. | Btk inhibitors |
| EP4192587A1 (en) | 2020-08-07 | 2023-06-14 | Biogen MA Inc. | Btk inhibitors |
| CN116917279A (zh) * | 2020-08-07 | 2023-10-20 | 渤健马萨诸塞州股份有限公司 | Btk抑制剂 |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| MX2024000082A (es) * | 2021-06-21 | 2024-03-05 | Beigene Switzerland Gmbh | Ligandos de crbn con (r)-glutarimida y métodos de uso. |
| IL313509A (en) * | 2021-12-30 | 2024-08-01 | Beigene Switzerland Gmbh | Reduction of proton tyrosine kinase (btk) by fusing btk inhibitors with an e3 ligase ligand and methods of use |
| CN116891437B (zh) * | 2022-04-06 | 2025-10-28 | 长春金赛药业有限责任公司 | 氨基酸衍生物、药物组合物及其制备方法和应用 |
| KR20250127267A (ko) | 2023-01-04 | 2025-08-26 | 에이비 사이언스 | 튜불린 중합 억제제 |
| CN117088851A (zh) * | 2023-07-13 | 2023-11-21 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US833429A (en) * | 1902-07-31 | 1906-10-16 | Anthony Van Wagenen | Automatic system of intercommunication. |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| IL154240A0 (en) * | 2000-08-08 | 2003-07-31 | Ortho Mcneil Pharm Inc | 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| EP1713775A4 (en) * | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| PL1951684T3 (pl) * | 2005-11-01 | 2017-03-31 | Targegen, Inc. | Biarylowe meta-pirymidynowe inhibitory kinaz |
| UA109412C2 (uk) * | 2005-11-01 | 2015-08-25 | 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки | |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| DK2078007T3 (da) * | 2006-11-01 | 2011-12-12 | Chroma Therapeutics Ltd | Ikk-beta-serin-threonin-proteinkinasehæmmere |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8809273B2 (en) * | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| JP5479346B2 (ja) * | 2007-10-05 | 2014-04-23 | ベラステム・インコーポレーテッド | ピリミジン置換プリン誘導体 |
| JP5743897B2 (ja) * | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化合物 |
| WO2011029043A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| WO2011029046A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
| US8334292B1 (en) * | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| CA2815330A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| WO2012133310A1 (ja) | 2011-03-31 | 2012-10-04 | 美津濃株式会社 | アイアンゴルフクラブヘッドおよびアイアンゴルフクラブ |
| AU2012242777A1 (en) | 2011-04-12 | 2013-10-31 | Alzheimer's Institute Of America, Inc. | Compositions and therapeutic uses of IKK-related kinase epsilon and TANKbinding kinase 1 inhibitors |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| ES2713196T3 (es) | 2013-12-11 | 2019-05-20 | Biogen Ma Inc | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| PT3080103T (pt) * | 2013-12-11 | 2018-07-23 | Sunesis Pharmaceuticals Inc | Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia |
| WO2015187089A1 (en) * | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse För Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
| CA2960401C (en) * | 2014-10-06 | 2022-07-26 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
| MA42510A (fr) | 2015-06-10 | 2018-06-06 | Biogen Ma Inc | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton |
| JOP20190233A1 (ar) | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2014
- 2014-12-11 PT PT148250012T patent/PT3080103T/pt unknown
- 2014-12-11 ES ES14825001.2T patent/ES2678021T3/es active Active
- 2014-12-11 LT LTEP14825001.2T patent/LT3080103T/lt unknown
- 2014-12-11 PL PL14825001T patent/PL3080103T3/pl unknown
- 2014-12-11 KR KR1020167018533A patent/KR102413253B1/ko active Active
- 2014-12-11 JP JP2016538524A patent/JP6431914B2/ja active Active
- 2014-12-11 AU AU2014362231A patent/AU2014362231B2/en active Active
- 2014-12-11 HU HUE14825001A patent/HUE040346T2/hu unknown
- 2014-12-11 BR BR112016012860A patent/BR112016012860A2/pt not_active Application Discontinuation
- 2014-12-11 WO PCT/US2014/069853 patent/WO2015089337A1/en not_active Ceased
- 2014-12-11 MY MYPI2016702033A patent/MY179781A/en unknown
- 2014-12-11 HR HRP20181109TT patent/HRP20181109T1/hr unknown
- 2014-12-11 CA CA2932608A patent/CA2932608C/en active Active
- 2014-12-11 TW TW108127236A patent/TWI744672B/zh active
- 2014-12-11 DK DK14825001.2T patent/DK3080103T3/en active
- 2014-12-11 EP EP21168048.3A patent/EP3872075A1/en active Pending
- 2014-12-11 CN CN201480071422.6A patent/CN106459002B/zh active Active
- 2014-12-11 MX MX2019014228A patent/MX388978B/es unknown
- 2014-12-11 CN CN201810840975.3A patent/CN108947913A/zh active Pending
- 2014-12-11 TW TW103143378A patent/TWI608002B/zh active
- 2014-12-11 SG SG11201604595VA patent/SG11201604595VA/en unknown
- 2014-12-11 EA EA201792348A patent/EA037942B1/ru unknown
- 2014-12-11 EA EA201691114A patent/EA030538B1/ru unknown
- 2014-12-11 EP EP14825001.2A patent/EP3080103B9/en active Active
- 2014-12-11 AR ARP140104620A patent/AR098721A1/es active IP Right Grant
- 2014-12-11 TW TW106124589A patent/TWI675833B/zh active
- 2014-12-11 RS RS20180830A patent/RS57662B1/sr unknown
- 2014-12-11 CN CN201810840784.7A patent/CN109096274B/zh active Active
- 2014-12-11 EP EP18160575.9A patent/EP3357921A3/en not_active Withdrawn
- 2014-12-11 MX MX2016007611A patent/MX370103B/es active IP Right Grant
- 2014-12-11 SI SI201430795T patent/SI3080103T1/sl unknown
- 2014-12-11 SG SG10201908558W patent/SG10201908558WA/en unknown
- 2014-12-11 US US15/103,749 patent/US9809577B2/en active Active
- 2014-12-11 SM SM20180373T patent/SMT201800373T1/it unknown
- 2014-12-11 NZ NZ721217A patent/NZ721217A/en unknown
-
2016
- 2016-06-05 IL IL24603116A patent/IL246031B/en active IP Right Grant
- 2016-06-09 SA SA518391170A patent/SA518391170B1/ar unknown
- 2016-06-10 PH PH12016501107A patent/PH12016501107B1/en unknown
- 2016-06-10 CL CL2016001435A patent/CL2016001435A1/es unknown
-
2017
- 2017-06-08 CL CL2017001459A patent/CL2017001459A1/es unknown
- 2017-09-08 US US15/699,857 patent/US10081619B2/en active Active
- 2017-09-14 ZA ZA2017/06244A patent/ZA201706244B/en unknown
- 2017-12-08 JP JP2017236092A patent/JP6526167B2/ja active Active
- 2017-12-15 AR ARP170103535A patent/AR110381A2/es unknown
-
2018
- 2018-07-18 CY CY20181100755T patent/CY1120517T1/el unknown
- 2018-08-22 US US16/108,755 patent/US10759783B2/en active Active
-
2019
- 2019-03-22 AU AU2019201997A patent/AU2019201997C1/en active Active
- 2019-05-07 JP JP2019087573A patent/JP2019163280A/ja not_active Withdrawn
- 2019-09-23 IL IL269569A patent/IL269569B/en active IP Right Grant
-
2020
- 2020-08-27 US US17/004,411 patent/US11572356B2/en active Active
-
2021
- 2021-03-15 JP JP2021041198A patent/JP7076022B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ721217A (en) | Biaryl inhibitors of bruton’s tyrosine kinase | |
| IN2014DN10576A (enExample) | ||
| MX2015015421A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| MX2018005292A (es) | Inhibidores de acc y usos de los mismos. | |
| MX2015015417A (es) | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. | |
| PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| MX2018006288A (es) | Inhibidores de acc tipo ester y usos de los mismos. | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| MX356753B (es) | Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| EA201591960A1 (ru) | Ингибиторы акк и их применение | |
| MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
| IL259863B (en) | Polycyclic compounds as inhibitors of proton tyrosine kinase | |
| EA201591962A1 (ru) | Ингибиторы акк и их применение | |
| JO3793B1 (ar) | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها | |
| EA201590268A1 (ru) | Ариллактамные ингибиторы киназы | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
| EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
| MX2019000884A (es) | Formas de succinato y composiciones de inhibidores de la tirosina cinasa de bruton. | |
| MA39824A (fr) | Composés azole amido-substitués | |
| NZ743260A (en) | Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors | |
| NZ737572A (en) | Intermediate compounds for the preparation of bipiperidine-2-one compounds | |
| PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 3466520, BIOGEN MA INC., 225 BINNEY STREET , CAMBRIDGE MA 02142, US Effective date: 20191112 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 DEC 2023 BY ANAQUA SERVICES Effective date: 20221124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 DEC 2024 BY ANAQUA SERVICES Effective date: 20231122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 DEC 2025 BY ANAQUA SERVICES Effective date: 20241121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 DEC 2026 BY ANAQUA SERVICES Effective date: 20251120 |